|
| 37838086 | Microsatellite Instability and Mismatch Repair Deficiency Define a Distinct Subset of Lung Cancers Characterized by Smoking Exposure, High Tumor Mutational Burden, and Recurrent Somatic MLH1 Inactivation. | J Thorac Oncol | 2024 |
| 37796533 | Decision-making as discovery: Vetting clinical research in a leading precision oncology service. | Sociol Health Illn | 2024 |
| 37849038 | Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer. | Cancer Discov | 2024 |
| 36122315 | Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial. | J Clin Oncol | 2023 |
| 38084089 | Precision Oncology: 2023 in Review. | Cancer Discov | 2023 |
| 37627175 | <i>RET</i>-Altered Cancers-A Tumor-Agnostic Review of Biology, Diagnosis and Targeted Therapy Activity. | Cancers (Basel) | 2023 |
| 37972337 | Amplification of Wild-Type <i>RET</i> Represents a Novel Molecular Subtype of Several Cancer Types With Clinical Response to Selpercatinib. | JCO Precis Oncol | 2023 |
| 37769225 | Important Considerations for Real-World Analysis of Neurotrophic Tyrosine Receptor Kinase Fusion Cancer and Tropomyosin Receptor Kinase Inhibitors. | JCO Precis Oncol | 2023 |
| 37769113 | Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas. | Cancer | 2023 |
| 37087124 | In Reply to "Selpercatinib Controls Central Nervous System Disease in Patients With RET Fusion-Positive NSCLC". | J Thorac Oncol | 2023 |
| 37451181 | A demand-offer critical analysis of current drug development. Phase I drugs versus TCGA sequencing data. | Eur J Cancer | 2023 |
| 37182602 | Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification. | J Thorac Oncol | 2023 |
| 37274265 | Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage <i>RET</i> fusion-positive non-small cell lung cancer. | Front Oncol | 2023 |
| 37269335 | SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy. | Cancer Discov | 2023 |
| 37262390 | Response to Repotrectinib After Development of <i>NTRK</i> Resistance Mutations on First- and Second-Generation TRK Inhibitors. | JCO Precis Oncol | 2023 |
| 36996726 | Organizing precision medicine: A case study of Memorial Sloan Kettering Cancer Center's engagement in/with genomics. | Soc Sci Med | 2023 |
| 36996322 | Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers. | Clin Cancer Res | 2023 |
| 36780766 | Characterization of Central Nervous System Clinico-Genomic Outcomes in ALK-Positive Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Alectinib. | Lung Cancer | 2023 |
| 36610231 | Precision oncology using organoids of a secretory carcinoma of the salivary gland treated with TRK-inhibitors. | Oral Oncol | 2023 |
| 36511802 | NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations. | Cancer Discov | 2023 |
| 36806787 | Rare molecular subtypes of lung cancer. | Nat Rev Clin Oncol | 2023 |
| 36682841 | Response to Provenzano et al. and De Carlo et al. | J Thorac Oncol | 2023 |
| 36907745 | Trends in location of death for individuals with metastatic lung cancer in the United States. | Am J Surg | 2023 |
| 36657661 | Central Nervous System Disease in Patients With RET Fusion-Positive NSCLC Treated With Selpercatinib. | J Thorac Oncol | 2023 |
| 34480094 | NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types. | Br J Cancer | 2022 |
| 35383193 | Author Correction: The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers. | Nat Commun | 2022 |
| 35476549 | ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series. | JCO Precis Oncol | 2022 |
| 35705558 | Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. | Nat Commun | 2022 |
| 35704797 | Selpercatinib-Induced Hypothyroidism Through Off-Target Inhibition of Type 2 Iodothyronine Deiodinase. | JCO Precis Oncol | 2022 |
| 35672677 | Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib. | BMC Cancer | 2022 |
| 35536733 | Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers. | Oncologist | 2022 |
| 35430374 | Clinical Utility and Performance of an Ultrarapid Multiplex RNA-Based Assay for Detection of ALK, ROS1, RET, and NTRK1/2/3 Rearrangements and MET Exon 14 Skipping Alterations. | J Mol Diagn | 2022 |
| 35394532 | An Ascendant Challenge: Central Nervous System Metastases in ALK+ Lung Cancers. | Clin Cancer Res | 2022 |
| 35788405 | Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy. | J Thorac Oncol | 2022 |
| 35663414 | Long-Term Efficacy and Safety of Entrectinib in <i>ROS1</i> Fusion-Positive NSCLC. | JTO Clin Res Rep | 2022 |
| 35484264 | Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA. | Nat Med | 2022 |
| 35553647 | Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors. | Clin Cancer Res | 2022 |
| 36606522 | Testing methods to diagnose TRK fusion cancer - a plain language summary and patient perspective. | Future Oncol | 2022 |
| 36458431 | Precision Oncology: 2022 in Review. | Cancer Discov | 2022 |
| 36418296 | Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies. | Nat Commun | 2022 |
| 36108661 | Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. | Lancet Oncol | 2022 |
| 36108503 | Refining patient selection of MET-activated non-small cell lung cancer through biomarker precision. | Cancer Treat Rev | 2022 |
| 36044468 | Bioinformatically Expanded Next-Generation Sequencing Analysis Optimizes Identification of Therapeutically Relevant MET Copy Number Alterations in >50,000 Tumors. | Clin Cancer Res | 2022 |
| 36357680 | Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer. | Nat Med | 2022 |
| 36201714 | Outcomes With Local Therapy and Tyrosine Kinase Inhibition in Patients With <i>ALK</i>/<i>ROS1</i>/<i>RET</i>-Rearranged Lung Cancers. | JCO Precis Oncol | 2022 |
| 35950566 | LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA <i>RET</i> fusion-positive non-small-cell lung cancer. | Future Oncol | 2022 |
| 35947247 | Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors. | Invest New Drugs | 2022 |
| 35183775 | Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001. | J Thorac Oncol | 2022 |
| 35183043 | Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations. | ESMO Open | 2022 |
| 35149545 | MYC Promotes Tyrosine Kinase Inhibitor Resistance in ROS1-Fusion-Positive Lung Cancer. | Mol Cancer Res | 2022 |